NCT05056857 |
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen |
NCT05696626 |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
NCT05868226 |
PRE-I-SPY Phase I/Ib Oncology Platform Program |
NCT04768426 |
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer |
NCT06275126 |
Optimizing Surgical Decisions in Young Adults With Breast Cancer |
NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer |
NCT06133348 |
Promoting Resilience in Women With Breast Cancer |
NCT04673448 |
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer |
NCT04616248 |
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors |
NCT03351348 |
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control |
NCT06324357 |
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread |
NCT03090165 |
Ribociclib and Bicalutamide in AR+ TNBC |
NCT04329065 |
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer |
NCT04959474 |
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer |
NCT04692831 |
Testing a New Imaging Agent to Identify Cancer |
NCT05325866 |
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression |
NCT05693766 |
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort |
NCT05744557 |
Vapocoolant Analgesia for Breast Lymphoscintigraphy |
NCT06026657 |
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer |
NCT04319757 |
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors |
NCT04360330 |
SABER Study for Selected Early Stage Breast Cancer |
NCT04084730 |
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer |
NCT05946668 |
Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study |
NCT06086704 |
Study of 18F-FFNP Breast PET/MRI |
NCT04589468 |
Researching the Effect of Exercise on Cancer |
NCT06400472 |
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors |
NCT05607004 |
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
NCT05751668 |
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) |
NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
NCT04364672 |
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
NCT05568472 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study |
NCT02484404 |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... |
NCT04648904 |
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer |
NCT05020860 |
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
NCT05467891 |
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
NCT05483491 |
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer |
NCT05645380 |
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC |
NCT05646862 |
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy |
NCT05932862 |
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors |
NCT05123482 |
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies |
NCT05912231 |
Ultrahypofractionation and Normal Tissue Toxicity |
NCT03909282 |
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma |
NCT04998682 |
Prospective Evaluation of Targeted Axillary Dissection (TAD) |
NCT05856773 |
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy |
NCT05464082 |
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC |
NCT03930680 |
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane |
NCT05208762 |
A Study of SGN-PDL1V in Advanced Solid Tumors |
NCT04722692 |
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
NCT05544929 |
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers |
NCT05313191 |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors |
NCT05372640 |
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
NCT04771520 |
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors |
NCT05563220 |
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
NCT05132582 |
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer |
NCT03562273 |
GammaPod Registry and Quality of Life Nomogram |
NCT05888831 |
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors |
NCT05456373 |
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery |
NCT06081127 |
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function |
NCT03796273 |
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases |
NCT05340673 |
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer |
NCT05319873 |
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
NCT05092373 |
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax |
NCT06100874 |
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) |
NCT04308720 |
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer |
NCT05215574 |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors |
NCT04824027 |
Breast Elasticity Imaging During Neoadjuvant Chemotherapy |
NCT05113927 |
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. |
NCT04147494 |
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues |
NCT05472792 |
Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) |
NCT05914792 |
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery |
NCT06092892 |
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases |
NCT06245889 |
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC |
NCT04873362 |
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
NCT05969860 |
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer |
NCT05076760 |
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer |
NCT06001762 |
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer |
NCT04561362 |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies |
NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
NCT05269160 |
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ) |
NCT05000294 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
NCT05417594 |
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies |
NCT05747794 |
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy |
NCT05086692 |
A Beta-only IL-2 ImmunoTherapY Study |
NCT06157892 |
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors |
NCT05846789 |
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers |
NCT04967976 |
Breast Mesh Used in Two-staged Breast Reconstruction |
NCT06022029 |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. |
NCT02926729 |
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy |
NCT05150691 |
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors |
NCT06312176 |
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) |
NCT06471673 |
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer |
NCT02735746 |
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis |
NCT03801369 |
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer |
NCT06042569 |
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial |
NCT04009044 |
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast |
NCT06295744 |
Outcomes and Cosmesis With Whole Breast Irradiation and Boost |
NCT05887492 |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
NCT03804944 |
Converting HR+ Breast Cancer Into an Individualized Vaccine |
NCT05731791 |
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation |
NCT05852691 |
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
NCT05766891 |
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery |
NCT05864144 |
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
NCT05306340 |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
NCT02701244 |
A Registry Study of Breast Microseed Treatment |
NCT03671044 |
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients |
NCT04703244 |
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer |
NCT04282044 |
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies |
NCT04614194 |
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib |
NCT03043794 |
Study of Stereotactic Radiotherapy for Breast Cancer |
NCT05593094 |
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors |
NCT05377229 |
MarginProbe 2.0 Data Collection Protocol |
NCT05107674 |
A Study of NX-1607 in Adults With Advanced Malignancies |
NCT04703920 |
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer |
NCT04567420 |
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT06253520 |
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer |
NCT05020574 |
Microbiome and Association With Implant Infections |
NCT05412225 |
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer |
NCT06388122 |
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients |
NCT05848739 |
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors |
NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
NCT05952557 |
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) |
NCT05768139 |
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
NCT05501886 |
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) |
NCT05894239 |
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
NCT06188520 |
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors |
NCT04796220 |
Focused Ultrasound and Gemcitabine in Breast Cancer |
NCT06428682 |
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction |
NCT05807074 |
Impact of Topical Tranexamic Acid in Breast Reconstruction |
NCT05458674 |
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC |
NCT04606030 |
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) |
NCT04841148 |
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer |
NCT02632448 |
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer |
NCT02760030 |
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery |
NCT03524430 |
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy |
NCT04443348 |
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
NCT04699630 |
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer |
NCT06065748 |
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
NCT04973930 |
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer |
NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
NCT03572374 |
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job |
NCT04886531 |
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers |
NCT00898131 |
Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer |
NCT06393374 |
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) |
NCT06130826 |
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer |
NCT05756166 |
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer |
NCT05879926 |
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 |
NCT05491226 |
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation |
NCT04140526 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC |
NCT05720039 |
Robotic vs. Open NSM for Early Stage Breast Cancer |
NCT05230186 |
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells. |
NCT06315296 |
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer |
NCT04243616 |
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer |
NCT05382286 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT03960463 |
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds |
NCT04234386 |
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer |
NCT03546686 |
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer |
NCT04022616 |
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients |
NCT04568616 |
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
NCT04677816 |
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients |
NCT04871516 |
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer |
NCT06113016 |
Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors |
NCT05637216 |
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients |
NCT02743858 |
Lymphedema Surveillance Study |
NCT04799535 |
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring |
NCT03025035 |
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer |
NCT05716958 |
Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT |
NCT05553522 |
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
NCT03272334 |
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer |
NCT06219434 |
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer |
NCT05351424 |
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc |
NCT05037825 |
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors |
NCT02872025 |
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) |
NCT05453825 |
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors |
NCT04314401 |
National Cancer Institute "Cancer Moonshot Biobank" |
NCT04265872 |
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
NCT05501704 |
ETHAN - ET for Male BC |
NCT04606446 |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
NCT04175210 |
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) |
NCT05700669 |
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors |
NCT05245812 |
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy |
NCT02912312 |
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer |
NCT06099769 |
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer |
NCT05755269 |
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women |
NCT02772367 |
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients |
NCT04994067 |
Intra-Operative Radiation Registry |
NCT04090567 |
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
NCT05417867 |
Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Stage I-III Breast Cancer |
NCT05059444 |
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation |
NCT05023967 |
Metformin and Nightly Fasting in Women With Early Breast Cancer |
NCT05537740 |
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors |
NCT05929768 |
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer |
NCT04891068 |
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer |
NCT06027268 |
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer |
NCT03075072 |
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial |
NCT05464667 |
Preoperative Irradiation for Stage I Breast Cancer |
NCT00899301 |
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer |
NCT03270072 |
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients |
NCT04588246 |
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery |
NCT05703269 |
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy |
NCT05837767 |
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue |
NCT03606967 |
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer |
NCT06239467 |
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
NCT03846167 |
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT |
NCT04644068 |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies |
NCT05892068 |
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain |
NCT06246968 |
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer |
NCT05837455 |
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer |
NCT04475640 |
Cancer Genetic Testing in Ethnic Populations |
NCT05218044 |
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ |
NCT05046301 |
Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications |
NCT05705401 |
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer |
NCT06103669 |
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) |
NCT05795101 |
TRUDI: TDXD+Durva in HER2+/Low IBC |
NCT05130801 |
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery |
NCT04042701 |
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
NCT04003038 |
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery |
NCT02476786 |
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
NCT05289466 |
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation. |
NCT04756765 |
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer |
NCT04225117 |
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) |
NCT05252416 |
(VELA) Study of BLU-222 in Advanced Solid Tumors |
NCT03213041 |
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer |
NCT04993313 |
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study |
NCT04119024 |
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors |
NCT05142358 |
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose |
NCT04647916 |
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
NCT04457596 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
NCT06008158 |
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer |
NCT05463796 |
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer |
NCT05383196 |
Onvansertib + Paclitaxel In TNBC |
NCT03990896 |
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial |
NCT02290834 |
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer |
NCT05607017 |
Losartan in Prevention of Radiation-Induced Heart Failure |
NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
NCT05268224 |
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue |
NCT05585034 |
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors |
NCT04266249 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
NCT05590949 |
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors |
NCT04557449 |
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors |
NCT04862663 |
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) |
NCT05827614 |
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications |
NCT04906395 |
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer |
NCT06058650 |
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities |
NCT05507879 |
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer |
NCT04028479 |
The Registry of Oncology Outcomes Associated With Testing and Treatment |
NCT04990921 |
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer |
NCT06127979 |
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery |
NCT02276443 |
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative |
NCT05972343 |
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients |
NCT05654623 |
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. |
NCT04585750 |
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
NCT04899908 |
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases |
NCT03979508 |
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer |
NCT05161195 |
Roll-over Study to Allow Continued Access to Ribociclib |
NCT06220214 |
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer |
NCT05269381 |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors |
NCT05219695 |
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) |
NCT05933395 |
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor |
NCT06055881 |
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS) |
NCT05708950 |
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) |
NCT05545150 |
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study |
NCT05098210 |
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer |
NCT05138510 |
Sexual Health in Breast Cancer Patients |
NCT04636710 |
Refining Local-Regional Therapy for IBC |
NCT05082610 |
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab |
NCT05464810 |
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT06072612 |
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
NCT02927912 |
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
NCT04450706 |
Functional Precision Oncology for Metastatic Breast Cancer |
NCT06270706 |
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
NCT05898399 |
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients |
NCT05703399 |
Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study |
NCT04371913 |
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study |
NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
NCT04443413 |
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients |
NCT04851613 |
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer |
NCT02422641 |
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis |
NCT06165419 |
Definitive Radiation for High-Risk Spine Metastases |
NCT05748834 |
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer |
NCT03820141 |
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer |
NCT05029999 |
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer |
NCT06349642 |
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform |
NCT06085742 |
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer |
NCT04923542 |
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
NCT05007106 |
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) |
NCT04674306 |
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer |
NCT05561842 |
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries) |
NCT05505643 |
Cryoablation vs Lumpectomy in T1 Breast Cancers |
NCT04144023 |
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ |
NCT04049214 |
Perioperative Mindfulness Proposal |
NCT05251714 |
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer |
NCT05230810 |
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. |
NCT04389281 |
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma |
NCT06257264 |
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors |
NCT04965064 |
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling |
NCT06441890 |
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer |
NCT05252390 |
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
NCT06103864 |
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
NCT05694364 |
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies |
NCT05945290 |
Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer |
NCT05323955 |
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
NCT06049355 |
EMBRACE: Exercising Together |
NCT05534438 |
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer |
NCT06328738 |
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
NCT04517838 |
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer |
NCT05919108 |
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers |
NCT05500508 |
Oral AMXT 1501 Dicaprate in Combination With IV DFMO |
NCT03449238 |
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients |
NCT04584255 |
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer |
NCT03987555 |
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients |
NCT05382299 |
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT06006806 |
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy |
NCT05595499 |
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors |
NCT06443359 |
HYPOFRACTIONATED REGIONAL NODAL IRRADIATION IN BREAST CANCER |
NCT04553770 |
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
NCT03796559 |
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes |
NCT04787042 |
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 |
NCT05315700 |
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration |
NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
NCT02993159 |
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast |
NCT01185132 |
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
NCT05406232 |
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer |
NCT05216432 |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer |
NCT05786664 |
Breast Cancer Survivorship Biorepository |
NCT03945721 |
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
NCT05949021 |
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer |
NCT04373564 |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
NCT05378464 |
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer |
NCT04946864 |
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer |
NCT05677802 |
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer |
NCT03428802 |
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability |
NCT04849364 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer |
NCT02095184 |
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients |
NCT06144164 |
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer |
NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
NCT05826964 |
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
NCT04925284 |
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) |
NCT05755984 |
3D Printed Breast Models in the Surgical Management of Breast Cancer |
NCT05675579 |
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) |
NCT05963984 |
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants |
NCT05966584 |
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer |
NCT05633979 |
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer |
NCT03011684 |
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
NCT04478279 |
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors |
NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
NCT05524584 |
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer |
NCT01503190 |
The Immune System's Response to Young Women's Breast Cancer |
NCT06409390 |
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer |
NCT04205903 |
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer |
NCT06218303 |
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ |
NCT06179303 |
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer |
NCT06112379 |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
NCT05134779 |
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You |
NCT04986579 |
Scalp Cooling in MBC |
NCT04683679 |
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer |
NCT05650879 |
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer |
NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
NCT02945579 |
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy |
NCT06016738 |
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
NCT05069038 |
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy |
NCT03412643 |
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling |
NCT04197687 |
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery |
NCT03165487 |
Comparison of the Breast Tumor Microenvironment |
NCT06260332 |
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors |
NCT04230109 |
Sacituzumab Govitecan In TNBC |
NCT05207709 |
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype |
NCT05996107 |
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer |
NCT04233385 |
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery |
NCT04852887 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
NCT06260033 |
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer |
NCT05565534 |
Diabetes Care for Breast Cancer Patients |
NCT04711824 |
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
NCT04964934 |
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) |
NCT05305924 |
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer |
NCT05190770 |
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
NCT04169542 |
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery |
NCT04967352 |
Predicting Chronic Pain Following Breast Surgery |
NCT06273852 |
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors |
NCT02250352 |
Core Biopsies for Establishing a Breast Tumor Tissue Repository |
NCT05150652 |
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer |
NCT04985032 |
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) |
NCT05262400 |
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors |
NCT04389632 |
A Study of SGN-B6A in Advanced Solid Tumors |
NCT04174352 |
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
NCT05608252 |
VS-6766+Abema+Fulv in Met HR+/HER- BC |
NCT05374915 |
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) |
NCT06018337 |
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) |
NCT06052852 |
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies |
NCT06351332 |
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC |
NCT06105632 |
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment |
NCT05768932 |
BAL0891 in Patients With Advanced Solid Tumors |
NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
NCT04225585 |
Well-Being After Breast Cancer Surgery |
NCT05325632 |
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
NCT05978232 |
NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients |
NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
NCT04315233 |
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics |
NCT04570956 |
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk |
NCT04603209 |
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer |
NCT03568656 |
Study to Evaluate CCS1477 in Advanced Tumours |
NCT03941756 |
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma |
NCT04333706 |
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) |
NCT05095207 |
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer |
NCT04895709 |
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
NCT04300556 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |
NCT02694809 |
The PROMISE Study: Duavee in Women With DCIS |
NCT03694756 |
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer |
NCT04397185 |
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer |
NCT04650256 |
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences |
NCT03504488 |
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
NCT04893109 |
ATEMPT 2.0: Adjuvant T-DM1 vs TH |
NCT03971409 |
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
NCT06139107 |
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole |
NCT04965688 |
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition |
NCT05774678 |
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation |
NCT05190978 |
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction |
NCT02778685 |
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer |
NCT04862585 |
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel |
NCT05585788 |
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients |
NCT04837209 |
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer |
NCT05629585 |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) |
NCT05035407 |
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers |
NCT04704661 |
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
NCT05111561 |
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
NCT04143711 |
Study of DF1001 in Patients With Advanced Solid Tumors |
NCT04468061 |
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC |
NCT05710328 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial |
NCT05840211 |
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy |
NCT04454528 |
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy |
NCT05554211 |
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage |
NCT06110793 |
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
NCT04849871 |
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma |
NCT05902507 |
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer |
NCT05812807 |
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
NCT04563507 |
Combined Immunotherapies in Metastatic ER+ Breast Cancer |
NCT05291507 |
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System |
NCT01570998 |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery |
NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer |
NCT06185205 |
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy |
NCT05078398 |
Postoperative Opt-In Narcotics Treatment in Breast |
NCT03934905 |
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction |
NCT05296798 |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
NCT03765983 |
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases |
NCT06318897 |
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer |
NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
NCT00353483 |
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells |
NCT01000883 |
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior |
NCT06120283 |
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
NCT04815083 |
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery |
NCT01766297 |
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer |
NCT05704283 |
3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer |
NCT05746897 |
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors |
NCT05488483 |
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography |
NCT06300411 |
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery |
NCT05183828 |
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer |
NCT04549571 |
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions |
NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
NCT05226871 |
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies |
NCT05891171 |
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
NCT02264678 |
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents |
NCT05376878 |
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis |
NCT02807597 |
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment |
NCT03536897 |
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry |
NCT05307705 |
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
NCT05146297 |
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials |
NCT04075305 |
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study |
NCT05203445 |
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer |
NCT05950945 |
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
NCT05256745 |
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer |
NCT06129747 |
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast |
NCT04588545 |
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
NCT04494945 |
Identifying and Caring for Individuals With Inherited Cancer Syndrome |
NCT03742245 |
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
NCT05591547 |
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr |
NCT04569747 |
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
NCT03975647 |
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
NCT03321045 |
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
NCT04348747 |
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
NCT04150042 |
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells |
NCT04854005 |
Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation |
NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
NCT04427293 |
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) |
NCT05144698 |
RAPA-201 Therapy of Solid Tumors |
NCT05528133 |
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer |
NCT06058377 |
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
NCT05655598 |
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer |
NCT05288777 |
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer |
NCT05890677 |
The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema |
NCT06075953 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment |
NCT05064098 |
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients |
NCT05557877 |
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer |
NCT05070247 |
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
NCT05576077 |
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors |
NCT03412877 |
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer |
NCT05774951 |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
NCT05277051 |
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
NCT05554354 |
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) |
NCT03463954 |
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
NCT05514054 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
NCT05633654 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) |
NCT04638751 |
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients |
NCT05765851 |
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |